JP2023518439A - Mapt調節のためのオリゴヌクレオチド - Google Patents
Mapt調節のためのオリゴヌクレオチド Download PDFInfo
- Publication number
- JP2023518439A JP2023518439A JP2022556142A JP2022556142A JP2023518439A JP 2023518439 A JP2023518439 A JP 2023518439A JP 2022556142 A JP2022556142 A JP 2022556142A JP 2022556142 A JP2022556142 A JP 2022556142A JP 2023518439 A JP2023518439 A JP 2023518439A
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- antisense strand
- dsrna
- sense strand
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026025899A JP2026106461A (ja) | 2020-03-18 | 2026-02-20 | Mapt調節のためのオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991405P | 2020-03-18 | 2020-03-18 | |
| US62/991,405 | 2020-03-18 | ||
| US202063071106P | 2020-08-27 | 2020-08-27 | |
| US63/071,106 | 2020-08-27 | ||
| PCT/US2021/022688 WO2021188626A1 (en) | 2020-03-18 | 2021-03-17 | Oligonucleotides for mapt modulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026025899A Division JP2026106461A (ja) | 2020-03-18 | 2026-02-20 | Mapt調節のためのオリゴヌクレオチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518439A true JP2023518439A (ja) | 2023-05-01 |
| JP2023518439A5 JP2023518439A5 (cg-RX-API-DMAC7.html) | 2024-03-28 |
Family
ID=77768304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556142A Pending JP2023518439A (ja) | 2020-03-18 | 2021-03-17 | Mapt調節のためのオリゴヌクレオチド |
| JP2026025899A Pending JP2026106461A (ja) | 2020-03-18 | 2026-02-20 | Mapt調節のためのオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026025899A Pending JP2026106461A (ja) | 2020-03-18 | 2026-02-20 | Mapt調節のためのオリゴヌクレオチド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210363523A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121537A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023518439A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230004448A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115552006A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021238319A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3171246A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021188626A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2018237245A1 (en) | 2017-06-23 | 2018-12-27 | University Of Massachusetts | TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| JP2023521604A (ja) * | 2020-03-30 | 2023-05-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 |
| CA3174079A1 (en) | 2020-05-26 | 2021-12-02 | Anastasia Khvorova | Synthetic oligonucleotides having regions of block and cluster modifications |
| KR20240067943A (ko) * | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| US20250340872A1 (en) * | 2021-10-07 | 2025-11-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing tau expression |
| MX2024007056A (es) * | 2021-12-13 | 2024-06-24 | Lilly Co Eli | Agentes de interferencia de arn de mapt. |
| US20250171777A1 (en) * | 2022-02-11 | 2025-05-29 | Alnylam Pharmaceuticals, Inc. | Microtubule Associated Protein Tau (MAPT) iRNA Agent Compositions and Methods of Use Thereof |
| US20230392146A1 (en) * | 2022-03-11 | 2023-12-07 | University Of Massachusetts | Oligonucleotides for app modulation |
| WO2023193004A2 (en) * | 2022-04-01 | 2023-10-05 | Triplet Therapeutics, Inc. | Methods for the treatment of neurodegenerative disorders |
| CA3247389A1 (en) * | 2022-05-12 | 2023-11-16 | Dicerna Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MAPT |
| CA3246379A1 (en) * | 2022-05-13 | 2023-11-16 | Julius-Maximilians-Universität Würzburg | METHOD AND MOLECULES FOR REDUCING AXONAL TAU PROTEIN ACCUMULATION BY BLOCKING HNRNP R-MEDICATED MRNA TRANSPORT FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| WO2024073618A2 (en) * | 2022-09-29 | 2024-04-04 | Atalanta Therapeutics, Inc. | Sirna compositions and methods targeting microtubule associated protein tau nucleic acids |
| WO2024145474A2 (en) * | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
| WO2024201423A2 (en) * | 2023-03-30 | 2024-10-03 | Biorchestra Co., Ltd. | Microtubule-associated protein tau targeting sirnas and uses thereof |
| EP4698652A2 (en) * | 2023-04-20 | 2026-02-25 | Adarx Pharmaceuticals, Inc. | Mapt-modulating compositions and methods of use thereof |
| KR20260046111A (ko) * | 2023-08-01 | 2026-04-06 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | MAPT를 표적으로 하는 dsRNA 및 이의 의약적 용도 |
| KR20260085142A (ko) * | 2023-10-11 | 2026-06-08 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 미세소관 관련 단백질 tau(mapt)의 발현을 억제하기 위한 조성물 및 방법 |
| WO2025212467A1 (en) * | 2024-03-31 | 2025-10-09 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use |
| WO2025233849A2 (en) * | 2024-05-07 | 2025-11-13 | Janssen Pharmaceutica Nv | MAPT siRNA AND USES THEREOF |
| US20260167963A1 (en) * | 2024-08-29 | 2026-06-18 | Synerk Inc. | Compounds, Compositions and Methods for Reducing MAPT (TAU) Expression |
| WO2026090357A1 (en) * | 2024-10-24 | 2026-04-30 | Adarx Pharmaceuticals, Inc. | Mapt-modulating oligonucleotides for treating central nervous system diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530257A (ja) * | 2006-03-17 | 2009-08-27 | シレンティス・エセ・ア・ウ | Cns状態の治療 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| CA2585970A1 (en) * | 2004-10-27 | 2006-05-04 | Vanderbilt University | Mammalian genes involved in infection |
| WO2008124066A1 (en) * | 2007-04-05 | 2008-10-16 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
| WO2010141511A2 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| TWI702046B (zh) * | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| ES2820713T3 (es) * | 2015-03-25 | 2021-04-22 | Univ Degli Studi Di Trento | Terapia mediada por ARN interferente para enfermedades neurodegenerativas |
| EP3929293A3 (en) * | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017132669A1 (en) * | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| WO2020041769A1 (en) * | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| US20210115442A1 (en) * | 2019-08-23 | 2021-04-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
-
2021
- 2021-03-17 JP JP2022556142A patent/JP2023518439A/ja active Pending
- 2021-03-17 MX MX2022011516A patent/MX2022011516A/es unknown
- 2021-03-17 KR KR1020227031792A patent/KR20230004448A/ko active Pending
- 2021-03-17 AU AU2021238319A patent/AU2021238319A1/en active Pending
- 2021-03-17 CN CN202180034587.6A patent/CN115552006A/zh active Pending
- 2021-03-17 WO PCT/US2021/022688 patent/WO2021188626A1/en not_active Ceased
- 2021-03-17 US US17/204,480 patent/US20210363523A1/en not_active Abandoned
- 2021-03-17 EP EP21770963.3A patent/EP4121537A4/en active Pending
- 2021-03-17 CA CA3171246A patent/CA3171246A1/en active Pending
-
2025
- 2025-09-24 US US19/338,285 patent/US20260109982A1/en active Pending
-
2026
- 2026-02-20 JP JP2026025899A patent/JP2026106461A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530257A (ja) * | 2006-03-17 | 2009-08-27 | シレンティス・エセ・ア・ウ | Cns状態の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115552006A (zh) | 2022-12-30 |
| MX2022011516A (es) | 2023-01-04 |
| AU2021238319A1 (en) | 2022-10-06 |
| EP4121537A4 (en) | 2024-07-31 |
| EP4121537A1 (en) | 2023-01-25 |
| WO2021188626A1 (en) | 2021-09-23 |
| JP2026106461A (ja) | 2026-06-29 |
| CA3171246A1 (en) | 2021-09-23 |
| US20210363523A1 (en) | 2021-11-25 |
| US20260109982A1 (en) | 2026-04-23 |
| KR20230004448A (ko) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260109982A1 (en) | Oligonucleotides for mapt modulation | |
| JP2023522701A (ja) | Msh3調節のためのオリゴヌクレオチド | |
| JP2023518970A (ja) | 安定性の向上を有する修飾オリゴヌクレオチドの合成 | |
| US20220090069A1 (en) | Oligonucleotides for htt-1a modulation | |
| JP2025072451A (ja) | 安定性が増加した修飾オリゴヌクレオチド | |
| US20230193281A1 (en) | Oligonucleotides for sod1 modulation | |
| JP2025156319A (ja) | 組織特異的なapoe調節のためのオリゴヌクレオチド | |
| US20230313198A1 (en) | Oligonucleotides for mlh3 modulation | |
| JP2023550485A (ja) | Dgat2調節のためのオリゴヌクレオチド | |
| US20230392146A1 (en) | Oligonucleotides for app modulation | |
| US20230340475A1 (en) | Oligonucleotides for mlh1 modulation | |
| US20230348907A1 (en) | Oligonucleotides for mecp2 modulation | |
| JP2022528487A (ja) | C9orf72のオリゴヌクレオチドベースの調節 | |
| JP2023518268A (ja) | Snca調節のためのオリゴヌクレオチド | |
| US20240301410A1 (en) | Oligonucleotides for htt-1a modulation | |
| EP3277815A1 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
| JP2024523466A (ja) | IFN-γシグナル伝達経路の調節のためのオリゴヌクレオチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240315 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250616 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251021 |